SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kha vu who wrote (429)3/3/1998 12:23:00 AM
From: Bharat H. Barai  Read Replies (3) of 442
 
That is correct, as I understand from Timothy Hoogheem, CFO and Nanita Wadell. Once the shreholders approve the deal, the Shareholder gets $9 worth of Baxter stock, plus royalties of upto $2/share (to shareholders of record on merger date), based on 5% of sales of Somatogen products.

Clearly, Baxter got a super steal. Somatogen was sold dirt cheap!! I am surprised that even Lilly signed on the deal.

Bharat H. Barai MD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News